Microarray-based detection and expression analysis of extracellular matrix proteins in drug.resistant ovarian cancer cell lines

Oncology Reports

Volumn 32, Issue 5, 2014, Pages 1981-1990

  Januchowski, Radosław ^a   Zawierucha, Piotr ^a   Ruciñski, Marcin ^a   Zabel, Maciej ^a,b  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

CDNA microarray; Extracellular matrix; Multidrug resistance; Ovarian cancer

Indexed keywords

CISPLATIN; DOXORUBICIN; METHOTREXATE; PACLITAXEL; SCLEROPROTEIN; TOPOTECAN; VINCRISTINE; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER CELL CULTURE; CANCER CELL LINE; COL1A GENE; COL3A1 GENE; COL5A1 GENE; COL5A2 GENE; CONTROLLED STUDY; DCN GENE; DOWN REGULATION; DRUG RESISTANCE; EGFL6 GENE; FEMALE; GENE; GENE EXPRESSION; GPC3 GENE; HMCN1 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYBRIDIZATION; ITGA1 GENE; ITGB1BP3 GENE; KRT23 GENE; LAMA2 GENE; LUM GENE; MATN2 GENE; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; OVARY CANCER; POSTN GENE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RNA ISOLATION; TGFBI GENE; UPREGULATION; VIT GENE; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; OVARIAN NEOPLASMS; PROCEDURES; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; EXTRACELLULAR MATRIX PROTEINS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS;

EID: 84907292927     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3468     Document Type: Article

References (76)

1. Garcia M, Jemal A, Ward EM, et al: Global cancer facts & figures 2007. American Cancer Society, Atlanta, GA, 2007.
2. Kurman RJ (ed): Blaustein's Pathology of the Female Genital Tract. 5th edition. Springer, New York, NY, 2002.
3. Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, et al: Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR.2.2 trial. Lancet 361: 2099-2106, 2003.
4. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al: Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 28: 3323-3329, 2010.
5. Sehouli J, Stengel D, Oskay-Oezcelik G, Zeimet AG, Sommer H, Klare P, et al: Non platinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol 26: 3176-3182, 2008.
6. Choi CH: ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. Cancer Cell Int 5: 30, 2005.
7. Stupack DG and Cheresh DA: Get a ligand, get a life: integrins, signaling and cell survival. J Cell Sci 115: 3729-3738, 2002.
8. Sethi T, Rintoul RC, Moore SM, MacKinnon AC, Salter D, Choo C, et al: Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med 5: 662-668, 1999.
9. Iseri OD, Kars MD, Arpaci F and Gündüz U: Gene expression analysis of drug-resistant MCF-7 cells: implications for relation to extracellular matrix proteins. Cancer Chemother Pharmacol 65: 447-455, 2010.
10. Jain RK: The next frontier of molecular medicine: delivery of therapeutics. Nat Med 4: 655-657, 1998.
11. Tannock IF, Lee CM, Tunggal JK, Cowan DS and Egorin MJ: Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy. Clin Cancer Res 8: 878-884, 2002.
12. Netti PA, Berk DA, Swartz MA, Grodzinsky AJ and Jain RK: Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res 60: 2497-2503, 2000.
13. Jain RK: Transport of molecules in the tumor interstitium: a review. Cancer Res 47: 3039-3051, 1987.
14. Di Paolo A and Bocci G: Drug distribution in tumors: mechanisms, role in drug resistance, and methods for modification. Curr Oncol Rep 9: 109-114, 2007.
15. St Croix B, Florenes VA, Rak JW, Flanagan M, Bhattacharya N, Slingerland JM and Kerbel RS: Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents. Nat Med 2: 1204-1210, 1996.
16. St Croix B and Kerbel RS: Cell adhesion and drug resistance in cancer. Curr Opin Oncol 9: 549-556, 1997.
17. Dalton WS: The tumor microenvironment as a determinant of drug response and resistance. Drug Resist Updat 2: 285-288, 1999.
18. Chauhan VP, Stylianopoulos T, Boucher Y and Jain R: Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies. Annu Rev Chem Biomol Eng 2: 281-298, 2011.
19. Ramanujan S, Pluen A, McKee TD, Brown EB, Boucher Y and Jain RK: Diffusion and convection in collagen gels: implications for transport in the tumor interstitium. Biophys J 83: 1650-1660, 2002.
20. Dietel M, Bals U, Schaefer B, Herzig I, Arps H and Zabel M: In vitro prediction of cytostatic drug resistance in primary cell cultures of solid malignant tumours. Eur J Cancer 29A: 416-420, 1993.
21. Leonard GD, Fojo T and Bates SE: The role of ABC transporters in clinical practice. Oncologist 8: 411-424, 2003.
22. Januchowski R, Zawierucha P, Andrzejewska M, Ruci.ski M and Zabel M: Microarray-based detection and expression analysis of ABC and SLC transporters in drug-resistant ovarian cancer cell lines. Biomed Pharmacother 67: 240-245, 2013.
23. Januchowski R, Wojtowicz K, Sujka-Kordowska P, Andrzejewska M and Zabel M: MDR gene expression analysis of six drug-resistant ovarian cancer cell lines. Biomed Res Int 2013: 241763, 2013.
24. Januchowski R, Zawierucha P, Ruciski M, Nowicki M and Maciej Zabel: Extracellular matrix proteins expression profiling in chemoresistant variants of the A2780 ovarian cancer cell line. Biomed Res Int 2014: 365867, 2014.
25. Liang Y, Meleady P, Cleary I, McDonnell S, Connolly L and Clynes M: Selection with melphalan or paclitaxel (Taxol) yields variants with different patterns of multidrug resistance, integrin expression and in vitro invasiveness. Eur J Cancer 37: 1041-1052, 2001.
26. Correia AL and Bissell MJ: The tumor microenvironment is a dominant force in multidrug resistance. Drug Resist Updat 15: 39-49, 2012.
27. Varma RR, Hector SM, Clark K, Greco WR, Hawthorn L and Pendyala L: Gene expression profiling of a clonal isolate of oxaliplatin-resistant ovarian carcinoma cell line A2780/C10. Oncol Rep 14: 925-932, 2005.
28. Sherman-Baust CA, Weeraratna AT, Rangel LB, Pizer ES, Cho KR, Schwartz DR, Shock T and Morin PJ: Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells. Cancer Cell 3: 377-386, 2003.
29. Ismail RS, Baldwin RL, Fang J, Browning D, Karlan BY, Gasson JC and Chang DD: Differential gene expression between normal and tumor-derived ovarian epithelial cells. Cancer Res 60: 6744-6749, 2000.
30. Brown E, McKee T, diTomaso E, Pluen A, Seed B, et al: Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation. Nat Med 9: 796-800, 2003.
31. Stylianopoulos T, Diop-Frimpong B, Munn LL and Jain RK: Diffusion anisotropy in collagen gels and tumors: the effect of fiber network orientation. Biophys J 99: 3119-3128, 2010.
32. Csiszar K: Lysyl oxidases: a novel multifunctional amine oxidase family. Prog Nucleic Acid Res Mol Biol 70: 1-32, 2001.
33. El-Haibi CP, Bell GW, Zhang J, Collmann AY, Wood D, Scherber CM, Csizmadia E, Mariani O, Zhu C, Campagne A, Toner M, Bhatia SN, Irimia D, Vincent-Salomon A and Karnoub AE: Critical role for lysyl oxidase in mesenchymal stem cell-driven breast cancer malignancy. Proc Natl Acad Sci USA 109: 17460-17465, 2012.
34. Baker AM, Cox TR, Bird D, Lang G, Murray GI, Sun XF, Southall S M, Wilson JR and Erler JT: The role of lysyl oxidase in SRC-dependent proliferation and metastasis of colorectal cancer. J Natl Cancer Inst 103: 407-424, 2011.
35. Shi W, Yang B, Li X, Sun S, Wang L and Jiao S: The effect of lysyl oxidase polymorphism on susceptibility and prognosis of nonsmall cell lung cancer. Tumour Biol 33: 2379-2383, 2012.
36. Wilgus ML, Borczuk AC, Stoopler M, Ginsburg M, Gorenstein L, Sonett JR and Powell CA: Lysyl oxidase: a lung adenocarcinoma biomarker of invasion and survival. Cancer 117: 2186-2191, 2011.
37. Ween MP, Oehler MK and Ricciardelli C: Transforming growth factor-beta-induced protein (TGFBI)/(βig-H3): a matrix protein with dual functions in ovarian cancer. Int J Mol Sci 13: 10461-10477, 2012.
38. Li B, Wen G, Zhao Y, Tong J and Hei TK: The role of TGFBI in mesothelioma and breast cancer: association with tumor suppression. BMC Cancer 12: 239, 2012.
39. Ma C, Rong Y, Radiloff DR, Datto MB, Centeno B, Bao S, Cheng W, Lin F, Jiang S, Yeatman TJ and Wang XF: Extracellular matrix protein βig-h3/TGFBI promotes metastasis of colon cancer by enhancing cell extravasation. Genes Dev 22: 308-321, 2008.
40. Timpl R, Rohde H, Robey PG, Rennard SI, Foidart JM and Martin GR: Laminin-A glycoprotein from basement membranes. J Biol Chem 254: 9933-9937, 1979.
41. r92,000 type IV collagenase expression and invasion in ovarian cancer cell lines. Cancer Res 57: 5416-5420, 1997.
42. Seeliger H, Camaj P, Ischenko I, Kleespies A, De Toni E N, Thieme SE, Blum H, Assmann G, Jauch KW and Bruns CJ: EFEMP1 expression promotes in vivo tumor growth in human pancreatic adenocarcinoma. Mol Cancer Res 7: 189-198, 2009.
43. Lin H, Huber R, Schlessinger D and Morin PJ: Frequent silencing of the GPC3 gene in ovarian cancer cell lines. Cancer Res 59: 807-810, 1999.
44. Kim H, Xu GL, Borczuk AC, Busch S, Filmus J, Capurro M, Brody JS, Lange J, D'Armiento JM, Rothman PB and Powell CA: The heparan sulfate proteoglycan GPC3 is a potential lung tumor suppressor. Am J Respir Cell Mol Biol 29: 694-701, 2003.
45. Miao HL, Pan ZJ, Lei CJ, Wen JY, Li MY, Liu ZK, Qiu ZD, Lin MZ, Chen NP and Chen M: Knockdown of GPC3 inhibits the proliferation of Huh7 hepatocellular carcinoma cells through down-regulation of YAP. J Cell Biochem 114: 625-631, 2013.
46. Sofeu Feugaing DD, Götte M and Viola M: More than matrix: the multifaceted role of decorin in cancer. Eur J Cell Biol 92: 1-11, 2013.
47. Teicher BA, Ikebe M, Ara G, Keyes SR and Herbst RS: Transforming growth factor-β 1 overexpression produces drug resistance in vivo: reversal by decorin. In Vivo 11: 463-472, 1997.
48. Liang S, Xu JF, Cao WJ, Li HP and Hu CP: Human decorin regulates proliferation and migration of human lung cancer A549 cells. Chin Med J 126: 4736-4741, 2013.
49. El Behi M, Krumeich S, Lodillinsky C, Kamoun A, Tibaldi L, Sugano G, De Reynies A, Chapeaublanc E, Laplanche A, Lebret T, Allory Y, Radvanyi F, Lantz O, Eiján AM, Bernard-Pierrot I and Théry C: An essential role for decorin in bladder cancer invasiveness. EMBO Mol Med 5: 1835-1851, 2013.
50. Yamano Y, Uzawa K, Saito K, Nakashima D, Kasamatsu A, Koike H, et al: Identification of cisplatin-resistance related genes in head and neck squamous cell carcinoma. Int J Cancer 126: 437-449, 2010.
51. Seya T, Tanaka N, Shinji S, Yokoi K, Koizumi M, Teranishi N, Yamashita K, Tajiri T, Ishiwata T and Naito Z: Lumican expression in advanced colorectal cancer with nodal metastasis correlates with poor prognosis. Oncol Rep 16: 1225-1230, 2006.
52. Robertson NG, Resendes BL, Lin JS, Lee C, Aster JC, Adams JC and Morton CC: Inner ear localization of mRNA and protein products of COCH, mutated in the sensorineural deafness and vestibular disorder, DFNA9. Hum Mol Genet 10: 2493-2500, 2001.
53. Mayne R, Ren ZX, Liu J, Cook T, Carson M and Narayana S: VIT-1: the second member of a new branch of the von Willebrand factor A domain superfamily. Biochem Soc Trans 27: 832-835, 1999.
54. Szabó E, Korpos E, Batmunkh E, Lotz G, Holczbauer A, Kovalszky I, Deák F, Kiss I, Schaff Z and Kiss A: Expression of matrilin-2 in liver cirrhosis and hepatocellular carcinoma. Pathol Oncol Res 14: 15-22, 2008.
55. Rupp C, Dolznig H, Puri C, Sommergruber W, Kerjaschki D, Rettig WJ and Garin-Chesa P: Mouse endosialin, a C-type lectin-like cell surface receptor: expression during embryonic development and induction in experimental cancer neoangiogenesis. Cancer Immun 6: 10, 2006.
56. Valdez Y, Maia M and Conway EM: CD248: reviewing its role in health and disease. Curr Drug Targets 13: 432-439, 2012.
57. 5integrins and promotes cell motility. Cancer Res 62: 5358-5364, 2002.
58. Xiao ZM, Wang XY and Wang AM: Periostin induces chemoresistance in colon cancer cells through activation of the PI3K/Akt/survivin pathway. Biotechnol Appl Biochem: Dec 24, 2013 (Epub ahead of print). doi: 10.1002/bab.1193.
59. LeClair R and Lindner V: The role of collagen triple helix repeat containing 1 in injured arteries, collagen expression, and transforming growth factor β signaling. Trends Cardiovasc Med 17: 202-205, 2007.
60. Wang P, Wang YC, Chen XY, Shen ZY, Cao H, Zhang YJ, Yu J, Zhu JD, Lu YY and Fang JY: CTHRC1 is upregulated by promoter demethylation and transforming growth factor-β1 and may be associated with metastasis in human gastric cancer. Cancer Sci 103: 1327-1333, 2012.
61. Kim HC, Kim YS, Oh HW, Kim K, Oh SS, Kim JT, Kim BY, Lee S J, Choe YK, Kim DH, Kim SH, Chae SW, Kim KD and Lee HG: Collagen triple helix repeat containing 1 (CTHRC1) acts via ERK-dependent induction of MMP9 to promote invasion of colorectal cancer cells. Oncotarget 5: 519-529, 2014.
62. Thompson CL, Klein BE, Klein R, Xu Z, Capriotti J, Joshi T, Leontiev D, Lee KE, Elston RC and Iyengar SK: Complement factor H and hemicentin-1 in age-related macular degeneration and renal phenotypes. Hum Mol Genet 16: 2135-2148, 2007.
63. Chim SM, Qin A, Tickner J, Pavlos N, Davey T, Wang H, Guo Y, Zheng MH and Xu J: EGFL6 promotes endothelial cell migration and angiogenesis through the activation of extracellular signalregulated kinase. J Biol Chem 286: 22035-22046, 2011.
64. Wang X, Gong Y, Wang D, Xie Q, Zheng M, Zhou Y, Li Q, Yang Z, Tang H, Li Y, Hu R, Chen X and Mao Y: Analysis of gene expression profiling in meningioma: deregulated signaling pathways associated with meningioma and EGFL6 overexpression in benign meningioma tissue and serum. PLoS One 7: e52707, 2012.
65. Ieri OD, Kars MD, Arpaci F, Atalay C, Pak I and Gündüz U: Drug resistant MCF-7 cells exhibit epithelial-mesenchymal transition gene expression pattern. Biomed Pharmacother 65: 40-45, 2011.
66. Griesmann H, Ripka S, Pralle M, Ellenrieder V, Baumgart S, Buchholz M, Pilarsky C, Aust D, Gress TM and Michl P: WNT5A-NFAT signaling mediates resistance to apoptosis in pancreatic cancer. Neoplasia 15: 11-22, 2013.
67. Lu L, Xue X, Lan J, Gao Y, Xiong Z, Zhang H, Jiang W, Song W and Zhi Q: MicroRNA-29a upregulates MMP2 in oral squamous cell carcinoma to promote cancer invasion and anti-Apoptosis. Biomed Pharmacother 68: 13-19, 2014.
68. Boulay A, Masson R, Chenard MP, et al: High cancer cell death in syngeneic tumors developed in host mice deficient for the stromelysin-3 matrix metalloproteinase. Cancer Res 61: 2189-2193, 2001.
69. Wu E, Mari BP, Wang F, Anderson IC, Sunday ME and Shipp MA: Stromelysin-3 suppresses tumor cell apoptosis in a murine model. J Cell Biochem 82: 549-555, 2001.
70. Noël A, Boulay A, Kebers F, et al: Demonstration in vivo that stromelysin-3 functions through its proteolytic activity. Oncogene 19: 1605-1612, 2000.
71. Dangi-Garimella S, Krantz SB, Barron MR, Shields MA, Heiferman MJ, Grippo PJ, Bentrem DJ and Munshi HG: Threedimensional collagen I promotes gemcitabine resistance in pancreatic cancer through MT1-MMP-mediated expression of HMGA2. Cancer Res 71: 1019-1028, 2011.
72. Liu YJ, Xu Y and Yu Q: Full-length ADAMTS-1 and the ADAMTS-1 fragments display pro-And antimetastatic activity, respectively. Oncogene 25: 2452-2467, 2006.
73. Nakada M, Miyamori H, Kita D, et al: Human glioblastomas overexpress ADAMTS-5 that degrades brevican. Acta Neuropathol 110: 239-246, 2005.
74. Schrohl AS, Meijer-van Gelder ME, Holten-Andersen MN, Christensen IJ, Look MP, Mouridsen HT, et al: Primary tumor levels of tissue inhibitor of metalloproteinases-1 are predictive of resistance to chemotherapy in patients with metastatic breast cancer. Clin Cancer Res 12: 7054-7058, 2006.
75. Klintman M, Ornbjerg Würtz S, Christensen IJ, Braemer Hertel P, Fernö M, Malmberg M, et al: Association between tumor tissue TIMP-1 levels and objective response to first-line chemotherapy in metastatic breast cancer. Breast Cancer Res Treat 121: 365-371, 2010.
76. L'Espérance S, Popa I, Bachvarova M, Plante M, Patten N, Wu L, Têtu B and Bachvarov D: Gene expression profiling of paired ovarian tumors obtained prior to and following adjuvant chemotherapy: Molecular signatures of chemoresistant tumors. Int J Oncol 29: 5-24, 2006.